TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers for R-baclofen Effects in Normal Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2015
At a glance
- Drugs Arbaclofen (Primary)
- Indications Pervasive child development disorders
- Focus Biomarker; Pharmacodynamics
- 09 Mar 2012 Planned end date changed from 1 Jul 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 09 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jun 2011 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.